BTK
Les inhibiteurs de la tyrosine kinase de Bruton (BTK) sont des composés qui ciblent spécifiquement et inhibent la BTK, une enzyme cruciale impliquée dans la signalisation du récepteur des cellules B et la régulation de l'angiogenèse. La BTK joue un rôle significatif dans la prolifération et la survie des cellules cancéreuses, en particulier dans les malignités hématologiques. En inhibant la BTK, ces composés peuvent perturber l'angiogenèse et la croissance tumorale, ce qui les rend précieux en thérapie anticancéreuse. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de la BTK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
158 produits trouvés pour "BTK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BMX-IN-1
CAS :BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosineFormule :C29H24N4O4SDegré de pureté :98.38%Couleur et forme :SolidMasse moléculaire :524.59BTK-IN-11
CAS :<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Formule :C26H22ClN5O3Couleur et forme :SolidMasse moléculaire :487.94BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Formule :C26H23N7O2Couleur et forme :SolidMasse moléculaire :465.51BTK inhibitor 13
CAS :BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).Formule :C29H26FN5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :511.55Pirtobrutinib
CAS :<p>Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.</p>Formule :C22H21F4N5O3Degré de pureté :99.76% - 99.94%Couleur et forme :SolidMasse moléculaire :479.43BTK-IN-18
CAS :BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Formule :C20H22Cl2N6OCouleur et forme :SolidMasse moléculaire :433.33(Rac)-PF-06250112
CAS :(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.Formule :C22H20F2N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :438.43BTK-IN-19
CAS :BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .Formule :C21H22Cl2N6OCouleur et forme :SolidMasse moléculaire :445.35TAK-020
CAS :TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formule :C18H17N5O3Degré de pureté :98.66%Couleur et forme :SolidMasse moléculaire :351.36BTK inhibitor 1
CAS :<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Formule :C24H23FN8O2Degré de pureté :98.24% - 98.91%Couleur et forme :SolidMasse moléculaire :474.49BMS-935177
CAS :BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formule :C31H26N4O3Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :502.56TQ-3959
CAS :TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Formule :C40H47N11O5Couleur et forme :SolidMasse moléculaire :761.87BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Formule :C29H25N5O4S2Couleur et forme :SolidMasse moléculaire :571.67(Rac)-Ibrutinib alkyne
CAS :(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Formule :C25H22N6O2Couleur et forme :SolidMasse moléculaire :438.48JAK3/BTK-IN-3
CAS :JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Formule :C22H28N8OCouleur et forme :SolidMasse moléculaire :420.51BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52BTK-IN-34
CAS :BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Formule :C22H29N3O4SMasse moléculaire :431.55BTK-IN-10
CAS :BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formule :C25H24F2N4O2Couleur et forme :SolidMasse moléculaire :450.48BMS-986143
CAS :BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formule :C31H24Cl2N4O4Couleur et forme :SolidMasse moléculaire :587.45HDHD4-IN-1
CAS :HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Formule :C12H22NO11PCouleur et forme :SolidMasse moléculaire :387.28
